B9061

Bicalutamide (CDX)

≥98% (HPLC), powder

• Sinonimo/i: Casodex, Cosudex, N-[4-Cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide
• Formula empirica (notazione di Hill): C₁₈H₁₄F₄N₂O₄S
• Numero CAS: 90357-06-5
• Peso molecolare: 430.37
• Numero MDL: MFCD00869971
• Codice UNSPSC: 12352200
• ID PubChem: 329773312
• NACRES: NA.77

Proprietà

• Saggio: ≥98% (HPLC)
• Stato: powder
• Condizioni di stoccaggio: desiccated; protect from light
• Solubilità: DMSO: >5 mg/mL; H₂O: insoluble
• Ideatore: AstraZeneca
• Stringa SMILE: CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc2ccc(C#N)c(c2)C(F)(F)F
• InChI: 1S/C18H14F4N2O4S/c1-17(26,10-29(27,28)14-6-3-12(19)4-7-14)16(25)24-13-5-2-11(9-23)15(8-13)18(20,21)22/h2-8,26H,10H2,1H3,(H,24,25); LKJPYSCBVHEWIU-UHFFFAOYSA-N
• Informazioni sul gene: human ... AR(367)

Descrizione

Applicazioni

Bicalutamide (CDX) has been used as an androgen receptor (AR) antagonist in prostate,[1] bladder cancer cell lines[2] and human fetal skeletal muscle cells.[3] It has also been used as a supplement in RPMI 1640 for culturing androgen-independent LNCaP (LNCaP-AI) cell line.[4]

Azioni biochim/fisiol

Bicalutamide (CDX) is a non-steriodal Androgen Receptor (AR) Antagonist and a pure antiandrogen.

Bicalutamide (CDX) is a non-steriodal Androgen Receptor (AR) antagonist and a pure antiandrogen. It acts via balancing histone acetylation/deacetylation and recruitment of coregulators. Bicalutamide (CDX) abolishes androgen-mediated expression. For example, MMP13 upregulation in prostate cancer, PLZF (promyelocytic leukemia zinc finger protein), and GADD45γ (growth arrest and DNA damage inducible, gamma). Bicalutamide (CDX) is inhibited by non-genomic, transcription-independent stimulation of PI3K/AKT phosphorylation by androgens.

Caratteristiche e vantaggi

This compound is a featured product for Gene Regulation research. Click here to discover more featured Gene Regulation products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

This compound is featured on the Nuclear Receptors (Steroids) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

This compound was developed by AstraZeneca. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Informazioni sulla sicurezza

• Pittogrammi: GHS08,GHS09
• Avvertenze: Danger
• Indicazioni di pericolo: H351,H360FD,H410
• Consigli di prudenza: P202 - P273 - P280 - P308 + P313 - P391 - P405
• Classi di pericolo: Aquatic Chronic 1 - Carc. 2 - Repr. 1B
• Codice della classe di stoccaggio: 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• Classe di pericolosità dell'acqua (WGK): WGK 3
• Punto d’infiammabilità (°F): Not applicable
• Punto d’infiammabilità (°C): Not applicable
• Dispositivi di protezione individuale: dust mask type N95 (US), Eyeshields, Gloves